Mark McKenna serves as Chairman and Chief Executive Officer of Prometheus Biosciences (Nasdaq: RXDX), a clinical-stage biotechnology company creating the first precision therapeutics for immune-mediated diseases. He brings more than 20 years of strategic leadership from the consumer, MedTech, pharmaceutical, and diagnostics sectors. Since joining Prometheus in 2019, Mr. McKenna has raised nearly $500 million in equity capital for the Company and led the top-performing biotech IPO of 2021, creating more than $2.5 billion of equity value and delivering a ~20x return for early investors. Previously, Mr. McKenna was a corporate officer of Bausch Health Companies and served as President of the subsidiary Salix Pharmaceuticals. There, he revitalized the gastroenterology business with a series of strategic acquisitions and product launches, doubling revenue to exceed $2 billion while enhancing operating margin. Earlier, Mr. McKenna served at Bausch + Lomb for more than a decade, most recently as SVP and General Manager of the US Vision Care business where he deployed more than $100 million in strategic investment, which led to 22% revenue CAGR in an otherwise mature market. Prior to Bausch + Lomb, he held several roles of increasing responsibility at Johnson & Johnson. Mr. McKenna holds a degree in Marketing from Arizona State University, earned an MBA from Azusa Pacific University, and was a Fellow at the Wharton School.

Mark Stenhouse has served as our Chief Operating Officer since March 2021. Previously, Mr. Stenhouse served as a member of our Board of Directors from April 2018 to October 2020 and then as an advisor to our company through February 2021. Mr. Stenhouse served as General Manager, Screening at Exact Sciences Corporation from November 2019 to January 2021 and as an advisor to the company through February 2021. Mr. Stenhouse served as President, Cologuard at Exact Sciences Corporation from April 2018 until November 2019. From October 2016 until March 2018, Mr. Stenhouse served as Vice President, U.S. Immunology at AbbVie, Inc., where he oversaw U.S. expansion into the immunology marketplace. From April 2010 until September 2016, Mr. Stenhouse served as Vice President and Vice President/General Manager, U.S. Immunology-Gastroenterology Franchise at AbbVie. From September 2006 through March 2010, Mr. Stenhouse held various senior management, marketing, and sales positions within Abbott Laboratories’ U.S. Immunology division. Mr. Stenhouse holds a B.B.A. from the College of Charleston.

Olivier Laurent, Ph.D., has served as our Chief Scientific Officer and Head of R&D since December 2021, having served as Chief Technology Officer and Head of R&D since joining our company in 2020. Previously, Dr. Laurent was Chief Scientific Officer at Intrepida Bio, an immuno-oncology company focused on developing novel antibodies for the treatment of fibrotic solid tumors. Before that, Dr. Laurent was Chief Scientific Officer at Dauntless Pharmaceuticals, a clinical-stage company developing products in the metabolic and oncology therapeutic areas. Dr. Laurent has 25 years of experience in scientific roles of increasing responsibility, including at Sanofi, Bayer Biotech, Genentech, and Pfizer. While at Pfizer, he was Director of Protein Science and Target Identification and built the company’s peptide bioinformatics group. Dr. Laurent holds a Ph.D. in Cell Biology from the University of Grenoble and is a graduate of the École Normale Supérieure de Lyon in France.

Allison Luo, M.D. has served as our Chief Medical Officer since August 2018. Prior to that, Dr. Luo concurrently served as Chief Medical Officer at Oppilan Pharma and Escalier Pharma since March 2017, and as Senior Vice President of Clinical Development for Gastroenterology at Progenity Inc. since June 2017. Before that, Dr. Luo was Vice President of Clinical Development at Ophthotech Corp., now Iveric bio, Inc., since September 2015. She was an Executive Director at Bristol Myers Squibb Company from September 2006 to October 2014, where she was responsible for inflammatory bowel disease and led the Phase 3 program for Orencia (abatacept) and the Phase 2 programs for eldelumab (anti-IP10 antibody) for ulcerative colitis and Crohn’s disease. Earlier in her career, Dr. Luo was a Medical Director at Abbott Laboratories where she submitted the Japanese NDA for Humira in rheumatoid arthritis and developed the clinical trial protocols for Humira in ulcerative colitis. Dr. Luo holds a B.S. in Biochemistry and an M.D. from Northwestern University.

Ms. Nori Ebersole has served as Chief People Officer since April 2021. Prior to joining Prometheus Biosciences, Ms. Ebersole served as EVP & Chief Human Resources Officer for Urovant Sciences, Inc (Nasdaq: UROV) from 2017 to 2021 until its $681M enterprise value take private merger with Sumitomo Dainippon at a 96% premium. In this role, she was instrumental in their 2018 IPO, building the board, executive, and senior leadership teams. She also led the development and execution of their diversity, equity and inclusion strategy, employment brand, talent acquisition, mission, vision and values strategies, and the build of the field sales and market access teams for commercial launch. Prior to Urovant, she was the Chief Human Resources Officer at Paul Hastings, LLP from 2015 to 2017. Ms. Ebersole also served 18 years at Allergan Inc., from 1994 to 2015, until their sale to Actavis for $70.5B. Ms. Ebersole earned a B.S. in Business Administration from the University of Southern California Marshall School of Business and serves on the board of Big Brothers, Big Sisters of Orange County.

Timothy K. Andrews has served as our General Counsel since November 2020. From October 2016 through December 2019, he served as General Counsel and Secretary for Sienna Biopharmaceuticals, Inc., a publicly traded, clinical-stage biotech company. Mr. Andrews served as the Head of Legal at Whitecap Biosciences LLC, a start-up company founded by former Allergan, Inc. research and development executives, from July 2015 to October 2016. Mr. Andrews served as Senior Corporate Counsel and Assistant Secretary at Allergan, Inc. from 2011 through 2015, where he had legal responsibility for U.S. and international business development transactions, including acquisitions, licensing, and partnerships, as well as corporate governance and securities law compliance. From 2006 to 2011, Mr. Andrews was a corporate attorney at Latham & Watkins LLP. He was previously a Business Analyst at Deloitte Consulting. Mr. Andrews holds a B.A. in Political Economy from the University of California, Berkeley and a J.D. from Loyola Law School, Los Angeles.

Mr. Chris Doughty serves as our Chief Business Officer. Mr. Doughty joined Prometheus in February 2021 from Strata Oncology, a precision oncology company, where he served as Vice President of Strategy and Business Development and led the organization’s pharma business development efforts. Before pursuing opportunities focused in precision medicine, Mr. Doughty began his career in strategy consulting, most recently serving as an Engagement Manager at McKinsey & Company and also having spent time at Kaufman Hall and Deloitte. Mr. Doughty holds an MBA from the University of Michigan’s Ross School of Business and a B.S.E. in Industrial & Operations Engineering from the College of Engineering at the University of Michigan.

Ms. Vika Brough has over 15 years of experience in public and private accounting roles. She started her career as an auditor at Ernst & Young Assurance practice in San Diego, California. During her 10 years as an auditor, Ms. Brough served many multinational public and private clients in life science, medical devices, and technology industries. After Ernst & Young, Ms. Brough was Head of Finance at Human Longevity, Inc., a genomics-based company in San Diego, where she oversaw financial planning, accounting, treasury, and procurement functions. Ms. Brough graduated from San Diego State University with a Bachelor of Accounting degree.